New therapies in systemic lupus erythematosus.
A new understanding of the pathogenesis of autoimmunity, the mechanisms of action of older drugs, the advent of target-specific biological therapies and pharmacogenomics has created multiple treatment options for the patient with systemic lupus erythematosus. These include topical therapies, more selective non-steroidal anti-inflammatory agents, hormonal interventions and a new generation of immune suppressives. Currently available strategies also include the use of intravenous gamma globulin, apheresis, stem-cell transplantation and antileprosy preparations alone or in combination with immune suppressives. A handful of biologicals have been studied in clinical trials. After two decades without new options for lupus patients practitioners now have a full menu of improved therapeutic options.
Solsky
Marilyn A
MA
Wallace
Daniel J
DJ
D001688:Biological Products / Q000627:therapeutic use; D001781:Blood Component Removal / Q000639:trends; D003131:Combined Modality Therapy / Q000639:trends; D003879:Dermatologic Agents / Q000627:therapeutic use; D015316:Genetic Therapy / Q000639:trends; D006728:Hormones / Q000627:therapeutic use; D006801:Humans; D007165:Immunosuppression Therapy / Q000639:trends; D018836:Inflammation Mediators / Q000627:therapeutic use; D008180:Lupus Erythematosus, Systemic / Q000628:therapy*
D001688:Biological Products; D003879:Dermatologic Agents; D006728:Hormones; D018836:Inflammation Mediators